Literature DB >> 9399017

Clinical applications of zolmitriptan (Zomig, 311C90).

R B Lipton1, W F Stewart.   

Abstract

Zolmitriptan (Zomig, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399017     DOI: 10.1177/0333102497017S1807

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

1.  Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.

Authors:  Mark Sculpher; David Millson; David Meddis; Lynne Poole
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  The cost effectiveness of stratified care in the management of migraine.

Authors:  P Williams; A J Dowson; A M Rapoport; J Sawyer
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 3.  Patient perceptions and treatment preferences in migraine management.

Authors:  David Dodick
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.